MRI-guided laser interstitial thermal therapy appears to be safe and effective for glioblastomas and may add an average of 2 months to life expectancy.
Researchers report that the same driving force that makes Zika so detrimental to unborn babies gives it promise as a cancer treatment.
A noncontrolled phase I study in recurrent metastatic glioblastoma showed 3-year survival was five times higher in patients treated with intratumoral PVSRIPO.
These are the first data to highlight the prognostic value of MGMT methylation beyond the IDH1/2 mutation status test currently used to help predict glioma patient survival outcomes.
Antibody-mediated, immunotherapeutic strategies targeting survivin, a key cancer-related protein, may offer benefit in a variety of cancers.
A USCF team has uncovered molecular insights into meningioma biology that could lead to new, less toxic treatment approaches.
Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies—PART 2: Existing Experience and Considerations for Future Trials
In Part 2 of this two-part series, we review the clinical evidence in support of combining immunotherapy with stereotactic radiosurgery for the treatment of brain metastases; examine controversies regarding radiation dose and fractionation, as well as temporal sequencing of multimodality treatment; and discuss future directions in combined therapy.
In Part 2 of this review article, we discuss the management of primary CNS lymphoma, focusing in particular on systemic therapies and radiation, as well as provide clinicians with a comprehensive overview by covering the key investigations that have brought us to our current state of knowledge, and studies that may guide future interventions.
Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies—PART 1: Principles of Combined Treatment
In this review, we highlight preclinical and clinical data to support the rationale for combination of stereotactic radiosurgery with immunotherapy for the treatment of brain metastases; describe some areas of controversy, especially with regard to radiation fractionation and the timing of combination therapy; and discuss ongoing research into multimodality treatment of CNS tumors.
Here, in Part 1, we will provide an overview of the epidemiology of primary CNS lymphoma, followed by a discussion of the diagnostic and staging evaluation. We will also review the current prognostication systems for primary CNS lymphoma.